ReCor Medical, Inc. develops investigational device that is intended to provide a transcatheter treatment for mitral valve insufficiency (regurgitation). The company also provides ultrasound therapy services to treat mitral regurgitation. The company was founded in 2009 and is based in Ronkonkoma, New York.
105 Comac Street
Ronkonkoma, NY 11779
Founded in 2009
ReCor Medical Announces Major Advances with its Ultrasound-Based Renal Denervation System
Jan 28 14
ReCor Medical announced major advances in its Paradise System(TM) for renal denervation (RDN), confirming its commitment to lead in the treatment of patients with resistant hypertension (HTN). The company announced that it has received CE-mark for the latest generation of its ultrasound-based renal denervation system. The first patients were treated with the new system in December, 2013 at the Universitats--Herzzentrum, Bad Krozingen, Germany, by Professor Thomas Zeller, MD and Dr. Elias Noory, MD. The Paradise System is the only CE-Marked RDN system that uses radial ultrasound as its energy source - as opposed to radio frequency (RF) electrical energy -- together with water-based convective cooling, allowing for the potential of faster procedures, more thorough renal denervation, and improved vessel safety.
ReCor Medical, Inc. Reports 100% Responder Rate at One-Year Follow-up in Clinical Trial of its Ultrasound-Based PARADISE Renal Denervation System for Treating Resistant Hypertension
Nov 5 12
ReCor Medical, Inc. has reported one-year follow-up data on patients who have been treated via renal denervation for their resistant hypertension with the company's PARADISE System the only CE-marked system for renal denervation that is based on ultrasound, not radiofrequency, energy. The data were presented at TCT 2012 from the podium by Peter Fitzgerald, M.D., Ph.D., Associate Professor of Medicine (Cardiology), Associate Professor of Electrical Engineering (by courtesy), and Co-Director of the Center for Research in Cardiovascular Interventions at Stanford University School of Medicine. Additionally, Dr. Fitzgerald serves as Director of Core Cardiovascular Analysis Lab at Stanford. The data showed that 100% (15/15) patients have responded favorably to their PARADISE treatment. Three of these responders are now out to one-year follow-up. The accepted industry standard for a 'responder' is defined as >10 mm Hg systolic office blood pressure reduction. The scientific literature demonstrates that only a 5 mm Hg reduction in blood pressure results in a 14% decrease in stroke, a 9% decrease in heart disease, and a 7% decrease in mortality.
ReCor Medical, Inc. Expands its Medical Advisory Board
Sep 28 12
ReCor Medical, Inc. announced that it has expanded its medical advisory board in anticipation of conducting post-market clinical studies of its next-generation PARADISE(R) System for treatment of resistant hypertension via renal denervation--the only system for renal denervation that is based on ultrasound, not radiofrequency, energy. The new medical advisors are: Peter J. Fitzgerald, M.D., Ph.D., Stanford University School of Medicine, Stanford, Calif.; Thomas Mabin, M.D., Vergelegen Medi-Clinic, South Africa; Krishna J. Rocha-Singh, M.D., Praririe Cardiovascular, Springfield, Ill; and Karl-Heinz Kuck, M.D., Ph.D., Asklepios Klinik, Hamburg, Germany. ReCor's medical advisory board also includes: Raoul Bonan, M.D., Montreal Heart Institute; Montreal, Quebec, Canada; Marc R. Sapoval, M.D., Ph.D., H pital Europ en, Georges-Pompidou, Paris, France; Gilles Montalescot, M.D., Ph.D., Piti -Salp tri re Hospital, Paris; Carlos E. Ruiz, M.D., Ph.D., Lennox Hill Heart & Vascular Institute, New York City; and, Renu Virmani, M.D., CVPath Institute, Gaithersburg, Maryland.